The abstract is read at the publisher; the summary is JClub's.
Empagliflozin (10 mg daily) improved Seattle Angina Questionnaire summary scores by 14.0 (4.2–23.9) at 90 days in 11 ANOCA patients with CMVD, with rebound after stopping.
- Why it matters: Endothelial dysfunction and coronary microvascular/vasomotor dysfunction in ANOCA lack targeted treatments, so the study tested whether SGLT2 inhibition could improve symptoms and endothelial dysfunction markers.
- What they did: An open-label pilot trial enrolled 11 ANOCA participants with CMVD and measured angina, inflammatory/oxidative biomarkers, and endothelial microvesicles at baseline, 45, and 90 days, plus post-discontinuation in N=5; stored serum was also tested in a serum-induced in vitro endothelial cell model.
- The result: At 45 and 90 days, empagliflozin reduced inflammatory cytokines, oxidative stress biomarkers, and inflammatory eEVs while increasing anti-inflammatory cytokines, antioxidants, and repair eEVs; in vitro it lowered endothelial apoptosis, eEV release, VCAM-1, and mitochondrial reactive oxygen species, all reversing after discontinuation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.